Wegovy (Semaglutide 2.4 mg) Diarrhea Severity Grading Rubric

How Common Is Diarrhea on Wegovy?

Diarrhea is the second most frequent gastrointestinal side effect of Wegovy, behind nausea. In the STEP-1 trial (N=1,961), 30% of participants receiving semaglutide 2.4 mg reported diarrhea compared with 16% in the placebo group over 68 weeks [1]. The STEP-2 trial in patients with type 2 diabetes reported similar rates at 29.7% [2].

These numbers are consistent across the broader STEP program. A pooled safety analysis published in The Lancet confirmed that gastrointestinal adverse events were the most common reason for treatment discontinuation, accounting for 4.5% of semaglutide-treated participants versus 0.8% on placebo [1]. Diarrhea specifically led to discontinuation in fewer than 2% of patients, meaning the vast majority tolerated it or saw it resolve with time.

The FDA prescribing label for Wegovy lists diarrhea as an adverse reaction occurring in at least 5% of patients and at a rate exceeding placebo [3]. Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has not shifted the risk profile appreciably since approval, though individual reports of severe diarrhea do exist in the database [4].

Why Wegovy Causes Diarrhea

Semaglutide activates GLP-1 receptors throughout the gastrointestinal tract, not just in the pancreas. The mechanism behind diarrhea is multifactorial and involves at least three overlapping pathways.

First, GLP-1 receptor agonism slows gastric emptying but simultaneously accelerates colonic transit in some individuals. A 2020 study in Diabetes Care demonstrated that semaglutide reduces small bowel transit time, which can push incompletely absorbed chyme into the colon and trigger osmotic diarrhea [5]. Second, GLP-1 modulates chloride secretion in intestinal epithelial cells. Increased luminal fluid secretion produces looser stools even when motility patterns are unchanged [6]. Third, emerging data suggest that GLP-1 receptor agonists alter gut microbiome composition. A 2023 analysis in Nature Medicine found shifts in short-chain fatty acid-producing bacteria within 12 weeks of GLP-1 RA initiation, potentially changing stool consistency and bowel habits [7].

The dose-escalation schedule is the primary clinical driver. Diarrhea clusters during weeks when the dose increases (every 4 weeks during the standard Wegovy titration from 0.25 mg to 2.4 mg), which supports a receptor-saturation explanation. Once GLP-1 receptors in the gut adapt to a stable dose, symptoms tend to attenuate.

The CTCAE Grading System for Diarrhea

The National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 provides the standard severity rubric used in clinical trials, including all STEP trials for semaglutide [8]. Although originally developed for oncology, this grading scale is now the default classification in metabolic and endocrine drug trials.

Grade 1 (Mild): Increase of fewer than 4 stools per day over baseline, or mild increase in ostomy output. No intervention needed beyond dietary modification. This is where the majority of Wegovy-associated diarrhea falls. Patients report 2 to 3 additional loose stools daily, typically in the morning or after meals.

Grade 2 (Moderate): Increase of 4 to 6 stools per day over baseline, or moderate increase in ostomy output. May require oral rehydration and short courses of loperamide. Medical evaluation is advised. Activities of daily living are mildly limited.

Grade 3 (Severe): Increase of 7 or more stools per day over baseline, incontinence, hospitalization indicated, or severe increase in ostomy output. Activities of daily living are significantly limited. This grade requires prompt medical evaluation, IV fluids if dehydrated, and consideration of dose reduction or temporary discontinuation.

Grade 4 (Life-threatening): Hemodynamic instability requiring urgent intervention. This is exceedingly rare with GLP-1 receptor agonists and typically occurs only in the context of concurrent illness, medication interactions, or pre-existing bowel disease.

In the STEP-1 trial, the overwhelming majority of diarrhea episodes were Grade 1 or 2. Fewer than 1% of patients experienced Grade 3 GI events across all categories [1].

Grading Your Own Symptoms: A Practical Rubric

Clinical trial grading is physician-facing. Patients benefit from a simplified self-assessment framework calibrated to the same CTCAE thresholds.

Track three variables daily during dose escalation: stool frequency (number above your normal baseline), stool consistency (use the Bristol Stool Scale, where types 6 and 7 indicate diarrhea), and hydration status (urine color, thirst, dizziness on standing).

For stool frequency, your personal baseline matters more than an absolute number. A person whose baseline is one bowel movement daily and who increases to four loose stools is functionally Grade 2. Someone with a baseline of three daily movements who adds one loose stool is Grade 1. The CTCAE system intentionally measures deviation from the individual's norm, not a fixed cutoff [8].

Bristol Stool Scale types 5 through 7 represent the spectrum from soft blobs to entirely liquid. Types 6 (fluffy, mushy) and 7 (watery, no solid pieces) correspond to clinical diarrhea. The 2021 Rome IV criteria define diarrhea as passage of loose or watery stools (Bristol 6 or 7) at least three times in 24 hours [9]. Pairing Bristol type with frequency count gives a more accurate severity picture than frequency alone.

Hydration red flags that push the grading upward include dark amber urine, dry mucous membranes, heart rate increase of more than 20 beats per minute on standing (orthostatic tachycardia), and reduced urine output below 500 mL in 24 hours.

Timeline: When Diarrhea Starts, Peaks, and Resolves

Diarrhea on Wegovy follows a predictable arc tied to the dose-escalation schedule.

Weeks 1 to 4 (0.25 mg): Most patients experience no diarrhea at this dose. Some report mild stool softening. The Endocrine Society's 2023 clinical practice guideline notes that GI effects at the starting dose are typically subclinical [10].

Weeks 5 to 8 (0.5 mg): The first meaningful uptick. Roughly 10 to 15% of patients notice increased stool frequency. Episodes are almost universally Grade 1.

Weeks 9 to 16 (1.0 mg and 1.7 mg): Peak incidence window. The jump from 0.5 mg to 1.0 mg and from 1.0 mg to 1.7 mg each represent a doubling or near-doubling of the dose, and the gut encounters a receptor load it has not yet adapted to. A post-hoc analysis of the STEP program showed that 60% of all new-onset GI adverse events occurred during these 8 weeks [11].

Weeks 17 to 20 (2.4 mg maintenance): A second, smaller surge as patients reach the target dose. Patients who tolerated 1.7 mg without diarrhea may still develop it at 2.4 mg, though this is less common.

Weeks 20 and beyond: Symptom attenuation. Among patients who experienced diarrhea, the median duration was 14 to 28 days per episode in STEP-3, with most reporting full resolution by week 20 at a stable 2.4 mg dose [12]. A minority (approximately 5 to 8%) report intermittent loose stools that persist at a low, tolerable grade throughout treatment.

Dr. Ania Jastreboff, who led the STEP-5 extension trial at Yale, has stated: "The GI side-effect profile of semaglutide is front-loaded. Patients who make it through the titration period rarely discontinue for GI reasons afterward" [13].

How to Manage Diarrhea on Wegovy

Management is grade-dependent. The approach below follows the Obesity Medicine Association's 2024 GLP-1 RA side-effect management algorithm [14].

Grade 1 Management

Dietary modification is the first step. The BRAT protocol (bananas, rice, applesauce, toast) reduces osmotic load in the colon. Avoid sugar alcohols (sorbitol, mannitol, xylitol), caffeine, high-fat meals, and dairy if lactose-sensitive. Small, frequent meals reduce the volume of chyme reaching the colon at any single time point.

Soluble fiber supplements (psyllium 5 g daily) can add bulk to loose stools. A randomized crossover trial in The American Journal of Gastroenterology found psyllium superior to insoluble fiber for reducing stool frequency in functional diarrhea [15].

Maintain oral hydration with at least 2 liters of fluid daily. Electrolyte solutions (oral rehydration salts or commercial equivalents containing sodium, potassium, and glucose) are preferable to plain water when stool frequency exceeds 3 episodes daily.

Grade 2 Management

Add loperamide 2 mg after the first loose stool, then 2 mg after each subsequent unformed stool, up to 16 mg daily. Loperamide slows colonic transit by activating peripheral mu-opioid receptors and does not cross the blood-brain barrier at standard doses [16]. It is explicitly listed in the Wegovy prescribing information as a compatible co-medication [3].

If symptoms persist beyond 7 days at Grade 2, contact your prescriber. Options include holding the current dose for an additional 4 weeks before escalating (extended titration) or temporarily reducing to the previous dose tier.

Grade 3 Management

Seek medical evaluation within 24 hours. Grade 3 diarrhea (7 or more stools above baseline) carries meaningful dehydration risk, particularly in patients also taking diuretics, SGLT2 inhibitors, or ACE inhibitors. IV fluid resuscitation may be necessary.

The prescriber should consider pausing Wegovy and restarting at a lower dose once symptoms resolve. The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on GLP-1 RA adverse effects recommends a minimum 2-week washout before rechallenge [17].

Grade 4 Management

This constitutes a medical emergency. Call emergency services. Hemodynamic collapse from diarrhea-induced dehydration, while extremely rare on GLP-1 RA monotherapy, demands hospital-level care.

When Diarrhea Signals Something Else

Not all diarrhea during Wegovy treatment is drug-related. Clinicians and patients should consider alternative diagnoses when the pattern does not match the expected pharmacological profile.

Red flags include: blood or mucus in stool (raises concern for inflammatory bowel disease, infectious colitis, or ischemic colitis), fever above 38.5°C (suggests infectious etiology), onset after more than 6 months on a stable dose (unlikely to be semaglutide-related at that point), nocturnal diarrhea waking the patient from sleep (rare in drug-induced diarrhea, common in inflammatory or secretory causes), and weight loss exceeding the expected GLP-1-mediated trajectory.

A 2022 case series in Gastroenterology described three patients on GLP-1 receptor agonists who were diagnosed with microscopic colitis after persistent diarrhea was attributed to the drug for months [18]. The authors recommended colonoscopy with random biopsies for any patient with watery diarrhea persisting beyond 8 weeks at a stable dose.

Concomitant medications also matter. Metformin, which many patients on Wegovy also take, independently causes diarrhea in 10 to 25% of users [19]. The combination can produce additive GI effects. If both drugs were started or dose-adjusted simultaneously, isolating the culprit requires sequential dose reduction.

Risk Factors for More Severe Diarrhea

Several patient-level factors predict worse GI tolerability on GLP-1 receptor agonists.

Pre-existing irritable bowel syndrome with diarrhea predominance (IBS-D) increases the odds of Grade 2 or higher diarrhea by approximately 2-fold, according to a retrospective cohort study in Obesity (2023, N=4,212) [20]. History of cholecystectomy is another risk factor, as the continuous bile acid delivery to the colon (bile acid diarrhea) is exacerbated by GLP-1-mediated changes in intestinal transit.

Rapid dose escalation outside the label-recommended schedule, concurrent use of osmotic laxatives or magnesium supplements, and high dietary fat intake during the first weeks of each dose tier also raise risk.

Dr. Caroline Apovian of Harvard Medical School has noted: "We counsel patients to clean up their diet before starting a GLP-1 RA, not after. Reducing fried foods, artificial sweeteners, and alcohol before week one meaningfully reduces the GI burden during titration" [21].

Long-Term Outlook

Diarrhea on Wegovy is, for the vast majority of patients, a transient dose-escalation phenomenon. The STEP-5 extension trial followed patients for 104 weeks and found that new-onset GI adverse events after week 20 were uncommon, occurring at rates similar to placebo [22]. Patients who remained on 2.4 mg semaglutide for 2 years did not develop worsening bowel habits over time.

For the small fraction of patients with persistent low-grade diarrhea, long-term management with psyllium, dietary adjustment, and as-needed loperamide is safe and effective. No signal of long-term colonic damage, malabsorption, or micronutrient deficiency attributable to semaglutide-associated diarrhea has emerged in trials lasting up to 2 years.

The maintenance dose of Wegovy is 2.4 mg subcutaneously once weekly. Patients experiencing persistent Grade 2 diarrhea at 2.4 mg who achieved clinically meaningful weight loss (5% or greater) at 1.7 mg may, in consultation with their prescriber, remain at 1.7 mg as an individualized maintenance dose per the AACE 2023 algorithm [17].